Global study tracks rare muscle disease to pave way for future treatments
NCT ID NCT06374719
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows children and adults worldwide who have a rare genetic muscle disease called TNNT1 myopathy. Researchers aim to document how the disease progresses over time, including survival and motor milestones. The goal is to identify reliable measures that can be used in future clinical trials for potential therapies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this study could identify key measures for future trials, potentially speeding up development of treatments for this rare muscle disease.
- What could go wrong
- This is an observational study, not a treatment trial. It will not directly test any therapy, and results may not lead to immediate clinical changes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMISH NEMALINE MYOPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Clinic for Special Children
RECRUITINGGordonville, Pennsylvania, 17529, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a single workout shield damaged muscles? a new trial investigates
- Continued anifrolumab treatment studied for lupus and related diseases
- Mind-Reading device aims to give voice to the paralyzed
- New handheld scanner could replace MRI for muscle disease monitoring
- ICU muscle mystery: new study aims to uncover why patients stay weak